CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Lifitegrast Ophthalmic +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05594745
NCT05594745Phase 4Completed
CompareCT.gov

Comparative Efficacy of Different Treatment Regimens in Patients With Dry Eye Disease and Meibomian Gland Dysfunction

Tauber Eye Center·interventional·Posted Oct 26, 2022·Updated Apr 12, 2023

In Brief

A Phase 4 clinical trial evaluating Lifitegrast Ophthalmic, Systane Free, and 1 other intervention for Dry Eye Syndromes. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedOct 26, 2022
Enrollment StartMar 2, 2021
Primary CompletionJan 21, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.7 years ago

Interventions

Lifitegrast Ophthalmicdrug

eyedrop

Systane Freedrug

eyedrop

Lipiflowdevice

thermal pulsation